Island Pharmaceuticals Concludes ISLA-101 Dosing Study with Positive Safety Review

Island Pharmaceuticals Ltd has successfully completed dosing all subjects in its ISLA-101 Single Ascending Dose study, with the Safety Review Committee confirming the safety and tolerability of all three doses based on available preliminary data.

ISLA-101, a well-known drug candidate, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases. Moving forward, blood samples from the study participants will be analyzed in the company's analytical laboratory to assess the levels of ISLA-101 in the blood. The company remains on track to report the data from this analysis in early 2024.